Edgewise Therapeutics selling $200M in stock to support drug commercialization
Edgewise Therapeutics plans to sell nearly 10 million shares of its common stock at $20.13, raising $200 million.
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, increased its research and development spending…
-
Streaming video provider Gaia Inc. (Nasdaq: GAIA) is publicly selling 1.6 million shares of its…
-
The board of directors at can manufacturing giant Ball Corp. has approved the repurchase of…
-
Nasdaq has warned Noodles & Co. that it could be delisted from the stock exchange…
